Actavis and Warner Chilcott to sell products to settle charges by FTC that their merger is 'uncompetitive'

28 September 2013

US generic drugmaker Actavis (NYSE: ACT) has agreed to sell all rights and assets to four generic pharmaceuticals – three oral contraceptives and an osteoporosis treatment – to settle US Federal Trade Commission charges that its proposed $8.5 billion acquisition of Ireland-based drugmaker Warner Chilcott (Nasdaq: WCRX) would be anticompetitive (The Pharma Letter May 20).

As part of the proposed settlement, Actavis is seeking FTC approval to sell the rights and assets for each drug to New Jersey, USA-based Amneal Pharmaceuticals.

The FTC’s proposed order is designed to preserve competition in each of the following pharmaceutical markets:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK